Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fostemsavir for cardiovascular risk in HIV
NCT07030920Phase 2Recruiting
- Sponsor
- Centre hospitalier de l’Université de Montréal
- Start
- Sep 2025
- Primary completion
- Oct 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of fostemsavir in human immunodeficiency virus infection (HIV), sponsored by Centre hospitalier de l’Université de Montréal. Started Sep 2025; status: recruiting.
02
Drugs
fostemsavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT07030920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07030920.